Biometra GmbH

Biometra GmbH
Name	Biometra GmbH
Type	Private
Industry	Biotechnology
Founded	1990
Founder	Norbert H. Rein
Headquarters	Göttingen, Germany
Products	Thermal cyclers, PCR instruments, gel documentation systems
Parent	Analytik Jena (since 2009)

Biometra GmbH is a German company specializing in the development and manufacture of laboratory instruments for nucleic acid amplification and analysis. Based in Göttingen, the firm produced thermal cyclers and related equipment used in molecular biology, clinical research, and biotechnology applications. Over its corporate lifetime Biometra interacted with major institutions and companies in the life sciences and diagnostics sectors.

History

Biometra emerged in the context of late 20th-century molecular biology advances associated with institutions such as Max Planck Society, Harvard University, Stanford University, MIT, and Cold Spring Harbor Laboratory, which popularized polymerase chain reaction technologies alongside inventors and organizations including Kary Mullis, Cetus Corporation, Hoffmann-La Roche, and PerkinElmer. The company’s founding paralleled milestones like the Human Genome Project and collaborations between industrial actors such as Roche Diagnostics, Thermo Fisher Scientific, and QIAGEN. During the 1990s and 2000s Biometra established product lines that addressed needs identified by researchers at University of Cambridge, University of Oxford, ETH Zurich, Karolinska Institute, and Max Planck Institute for Biophysical Chemistry. Strategic moves in the 2000s linked Biometra to European life science consolidation involving companies such as Eppendorf, Bio-Rad Laboratories, Agilent Technologies, and Siemens Healthcare. In 2009 Biometra became part of Analytik Jena, aligning with corporate ownership patterns similar to acquisitions by Merck Group and Bayer AG in the diagnostics and reagents markets.

Products and Technology

Biometra’s product portfolio focused on thermal cyclers, real-time PCR instruments, gel documentation systems and accessories used alongside reagents and consumables from suppliers like New England Biolabs, Roche, Thermo Fisher Scientific, Qiagen, and Promega Corporation. Instruments were designed to fit workflows typical at facilities such as Johns Hopkins University, University of California, Berkeley, NIH, CDC, and European Molecular Biology Laboratory laboratories performing tasks originally advanced by actors including Sanger Institute, Wellcome Trust, Cold Spring Harbor Laboratory, Broad Institute, and Dana-Farber Cancer Institute. Technical features commonly referenced industry standards from organizations such as International Organization for Standardization, European Medicines Agency, Food and Drug Administration, World Health Organization, and Clinical and Laboratory Standards Institute. Biometra systems interfaced with software and hardware ecosystems seen in products by Applied Biosystems, BioTek Instruments, Molecular Devices, PerkinElmer, and GE Healthcare.

Research and Development

R&D at Biometra reflected trends traced back to research at Max Planck Institute for Developmental Biology, University of California, San Francisco, Ludwig Maximilian University of Munich, University of Tokyo, and Peking University. Development efforts paralleled methodological innovations from groups like Craig Venter’s teams, technologies such as next-generation sequencing commercialized by Illumina and PacBio, and diagnostic advancements by Cepheid and Roche Molecular Systems. Collaborative research frequently intersected with grant-driven projects funded by entities including European Research Council, National Institutes of Health, Deutsche Forschungsgemeinschaft, and Wellcome Trust. R&D outcomes addressed applications in fields populated by practitioners at Karolinska Institutet, Memorial Sloan Kettering Cancer Center, Imperial College London, and Yale University.

Corporate Structure and Ownership

Originally an independent German enterprise, Biometra’s ownership trajectory mirrored consolidation dynamics in biotechnology exemplified by acquisitions such as Qiagen’s deals and Thermo Fisher Scientific’s mergers. The integration into Analytik Jena reflected a pattern similar to corporate groupings involving Becton Dickinson, Roche, Siemens, and Merck KGaA. Executive leadership interacted with regulatory and industry stakeholders including European Commission, Bundesministerium für Bildung und Forschung, German Patent and Trade Mark Office, and business networks like German Association of Research-Based Pharmaceutical Companies.

Market Presence and Customers

Biometra served academic, clinical, and industrial customers comparable to users at Harvard Medical School, Mayo Clinic, Cleveland Clinic, GlaxoSmithKline, Novartis, and Pfizer. Sales channels and distribution networks resembled relationships maintained by Agilent Technologies, Bio-Rad Laboratories, Eppendorf, and Thermo Fisher Scientific, reaching markets across Europe, United States, China, India, and Brazil. End users included researchers from institutions such as Columbia University, Princeton University, University of Chicago, Northwestern University, and governmental labs like Public Health England and Robert Koch Institute.

Intellectual Property and Certifications

Biometra protected innovations through patents filed in jurisdictions administered by organizations like the European Patent Office and United States Patent and Trademark Office, in a landscape populated by patentees such as Applied Biosystems, Roche, and Qiagen. Certification and quality management adhered to standards such as ISO 9001 and ISO 13485 and regulatory frameworks involving CE marking and IVDR processes similar to other diagnostics manufacturers. Compliance and accreditation referenced test and inspection authorities like TÜV Rheinland, DEKRA, and notified bodies engaged in medical device conformity assessment.

Category:Biotechnology companies of Germany